Intersecting Molecular Pathways in Cardiovascular Disease and Diabetes Mellitus: Emerging Roles of Inflammation and Therapeutics
Diabetes/Metabolism Research and Reviews · 2026-05 · 42 (4)
DOI: 10.1002/dmrr.70167 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 09.04.2026. Verfasst von Lilian Anagnostopoulou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, KAT General Hospital, Athens, Greece. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Inflammation, Hypoglycemic Agents, Diabetes Mellitus. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Diabetes mellitus (DM) and cardiovascular diseases (CVD) remain leading contributors to global morbidity and mortality, imposing a substantial burden on healthcare systems worldwide. The pathophysiological mechanisms underlying these conditions are complex and closely interconnected, with chronic low‐grade inflammation, oxidative stress, endothelial dysfunction, insulin resistance and dysregulated lipid metabolism serving as pivotal shared pathways. Persistent hyperglycaemia and metabolic imbalance in DM accelerate vascular injury and atherosclerotic progression, thereby significantly increasing cardiovascular risk. Consequently, therapeutic strategies that concurrently target both metabolic and cardiovascular dysfunction may offer meaningful clinical advantages and improved long‐term outcomes. In recent years, novel antidiabetic agents such as sodium–glucose co‐transporter 2 (SGLT‐2) inhibitors and glucagon‐like peptide‐1 (GLP‐1) receptor agonists have demonstrated not only glycaemic control but also substantial cardiovascular protection, including reductions in major adverse cardiovascular events, heart failure hospitalisations and renal disease progression. These pleiotropic effects extend beyond glucose lowering and involve modulation of inflammatory pathways, improvement of endothelial function, attenuation of oxidative stress and favourable haemodynamic changes. Additionally, emerging evidence highlights the role of the gut microbiota as a critical mediator in the bidirectional relationship between DM and CVD. Alterations in microbial composition and diversity, collectively termed dysbiosis, have been associated with systemic inflammation, impaired metabolic homoeostasis, increased intestinal permeability and the production of pro‐atherogenic metabolites such as trimethylamine N‐oxide. Understanding these microbiome‐related mechanisms may open new avenues for preventive and therapeutic interventions targeting the gut–metabolic–cardiovascular axis. This narrative review provides an updated and comprehensive overview of the molecular and cellular mechanisms linking DM and CVD, with particular emphasis on inflammatory signalling, metabolic dysregulation and the emerging influence of the gut microbiome in their shared pathogenesis and therapeutic modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Department, KAT General Hospital, Athens, Greece.
- First Department of Cardiology, National and Kapodistrian University of Athens, Hippokration General Hospital of Athens, Athens, Greece.
- Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Cardiology Department, Hippokration General Hospital of Athens, Athens, Greece.
- Internist Diabetologist, Hygeia Hospital, Athens, Greece.
ORCID-Profile: Nikolaos Ktenopoulos, Anastasios Apostolos, Christos Fragoulis, Panayotis Vlachakis, Marios Sagris, Nikias Milaras, Ioannis Kyriazis, Konstantinos Toutouzas
Zitieren
APA
Anagnostopoulou, L., Ktenopoulos, N., Apostolos, A., Fragoulis, C., Vlachakis, P., Karakasis, P., Sagris, M., Milaras, N., Drakopoulou, M., Synetos, A., Kyriazis, I., Ioannidis, I., Tsioufis, C., & Toutouzas, K. (2026). Intersecting Molecular Pathways in Cardiovascular Disease and Diabetes Mellitus: Emerging Roles of Inflammation and Therapeutics. Diabetes/Metabolism Research and Reviews, 42(4). https://doi.org/10.1002/dmrr.70167
Vancouver
Anagnostopoulou L, Ktenopoulos N, Apostolos A, Fragoulis C, Vlachakis P, Karakasis P, et al. Intersecting Molecular Pathways in Cardiovascular Disease and Diabetes Mellitus: Emerging Roles of Inflammation and Therapeutics. Diabetes/Metabolism Research and Reviews. 2026;42(4). doi:10.1002/dmrr.70167
BibTeX
@article{Anagnostopoulou2026,
author = {Anagnostopoulou, Lilian and Ktenopoulos, Nikolaos and Apostolos, Anastasios and Fragoulis, Christos and Vlachakis, Panayotis and Karakasis, Paschalis and Sagris, Marios and Milaras, Nikias and Drakopoulou, Maria and Synetos, Andreas and Kyriazis, Ioannis and Ioannidis, Ioannis and Tsioufis, Costas and Toutouzas, Konstantinos},
title = {Intersecting Molecular Pathways in Cardiovascular Disease and Diabetes Mellitus: Emerging Roles of Inflammation and Therapeutics},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2026},
volume = {42},
number = {4},
doi = {10.1002/dmrr.70167}
}
EUVIMED